Why is Kadmon holdings (KDMN) stock rising Wednesday?
Apr 14, 2022 · One share of KDMN stock can currently be purchased for approximately $9.50. How much money does Kadmon make? Kadmon has a market capitalization of $1.70 billion and generates $8.29 million in revenue each year.
Where can I buy shares of KDMN?
Apr 11, 2022 · NYSE:KDMN Kadmon Stock Forecast, Price & News $9.50 0.00 (0.00%) (As of 11/9/2021) Today's Range $9.50 $9.50 50-Day Range $9.50 $9.50 52-Week Range $3.19 $9.50 Volume 1,052 shs Average Volume 5.11 million shs Market Capitalization $1.70 billion P/E Ratio N/A Dividend Yield N/A Beta N/A Profile Chart Competitors Headlines Options Chain
How much money did KDMN make in 2020?
Dec 03, 2021 · KDMN 0.00 0.00 (0.00%) 4,234. Filter by: Real-Time.
What is the stock price target for Kadmon?
Nov 08, 2021 · Get the latest Kadmon Holdings, Inc. (KDMN) stock price quote with news, financials and other important investing information.
Is KDMN a good stock to buy?
Kadmon has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Who owns KDMN?
On July 27, 2016 the company's stock began trading on the NYSE under the symbol KDMN but switched to NASDAQ in October 2020. On 8 September 2021, Sanofi announced it would acquire the company for $1.9 billion. The deal completed in November and its stock was deregistered as it became a subsidiary of Sanofi.
What is KDMN stock?
KDMN Price/Volume StatsCurrent price$9.5052-week highPrev. close$9.4852-week lowDay low$9.48VolumeDay high$9.50Avg. volume50-day MA$8.58Dividend yield1 more row
What happened Kadmon stock?
As of November 9, 2021, Kadmon common stock will cease to be traded on the NASDAQ Global Select Stock Market and will be subsequently deregistered. Centerview Partners acted as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP acted as legal counsel to Sanofi.Nov 9, 2021
Where is Kadmon holdings located?
New York, NYCompany Description: Kadmon Holdings, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry.
What are Kadmon holdings?
Kadmon, a Sanofi Company, is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Is Sanofi stock a buy?
SNY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 12.64, while its industry has an average P/E of 14.77.Jul 8, 2021
Is Kadmon a buy right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last twelve months. There are currently 4 hold ratings and 2...
How were Kadmon's earnings last quarter?
Kadmon Holdings, Inc. (NASDAQ:KDMN) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.20) earnings per sha...
What price target have analysts set for KDMN?
6 brokerages have issued twelve-month target prices for Kadmon's shares. Their forecasts range from $9.00 to $20.00. On average, they anticipate Ka...
Who are Kadmon's key executives?
Kadmon's management team includes the following people: Harlan W. Waksal , President, Chief Executive Officer & Director Steven Meehan , Chief F...
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Ascendis Pharma A/S (ASND) , Arena Pharmaceuticals (ARNA) , Legend Biotech (LEGN) , Intra-Cel...
When did Kadmon IPO?
(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citig...
What is Kadmon's stock symbol?
Kadmon trades on the NASDAQ under the ticker symbol "KDMN."
Who are Kadmon's major shareholders?
Kadmon's stock is owned by a number of retail and institutional investors. Top institutional shareholders include CSS LLC IL (0.00%), Goldman Sachs...
Which major investors are selling Kadmon stock?
KDMN stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Wolverine Asset Man...
What is the Kadmon company?
What is Rosen Law Firm?
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), ...